Circulating Transforming Growth Factor beta 1 (TGF-β1) in Guillain-Barré syndrome: Decreased concentrations in the early course and increase with motor function

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 2, 1998, Pages 162-165

  Créange, Alain ^a,b   Bélec, Laurent ^b   Clair, Bernard ^a,c   Degos, Jean Denis ^b   Raphaël, Jean Claude ^a,c   Gherardi, Romain K ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Cytokine; Demyelinating neuropathy; Guillain Barr syndrome; Transforming growth factor 1

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; GUILLAIN BARRE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOTOR PERFORMANCE; PLASMAPHERESIS; PRIORITY JOURNAL; TIME;

ADJUVANTS, IMMUNOLOGIC; ALPHA-MACROGLOBULINS; CELL MOVEMENT; DISEASE PROGRESSION; HUMANS; HYDROCORTISONE; IMMUNOGLOBULINS, INTRAVENOUS; PLASMA CELLS; PLASMA EXCHANGE; POLYRADICULONEUROPATHY; PROSPECTIVE STUDIES; PSYCHOMOTOR DISORDERS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031954208     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.2.162     Document Type: Article

References (45)

1. Koski CL, Gratz E, Sutherland J, et al. Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome. Ann Neurol 1986;19:573-7.
2. Taylor WA, Hughes RAC. T lymphocyte activation antigens in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neurol Sci 1989;24:33-9.
3. Griffin JW, George R, Ho T. Macrophage systems in peripheral nerves. A review. J Neuropathol Exp Neurol 1993;52: 553-60.
4. Hartung H-P, Reinerss K, Schmidt B, et al. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991;30:48-53.
5. Hartung HP, Hughes RAC, Taylor WA, et al. T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 1990;40: 215-8.
6. Maimone D, Annuziata P, Simone IL, et al. Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 1993; 47:55-62.
7. Sharief MK, McLean B, Thompson EJ. Elevated serum levels of tumor necrosis factor-α in Guillain-Barré syndrome. Ann Neurol 1993;33:591-6.
8. Gherardi RK, Chouaib S, Malapert D, et al. Early weight loss and high serum tumor necrosis factor-α levels in polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes syndrome. Ann Neurol 1994;35:501-5.
9. Créange A, Belec L, Clair B, et al. Differential kinetics of circulating tumor necrosis factor (TNF)-α and soluble TNF receptor (sTNF-Rs) in patients with Guillain-Barré syndrome. J Neuroimmunol 1996;68:95-9.
10. Redford EJ, Hall SM, Smith KJ. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 1995;118:869-78.
11. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors 1988;8:1-9.
12. Créange A, Belec L, Clair B, et al. Circulating TGF-β1 levels parallel motor function in patients with Guillain-Barré syndrome [abstract]. Neurology 1996;46(suppl 4):A286.
13. Sindern E, Schweppe K, Ossege LM, et al. Potential role of transforming growth factor-β1 in terminating the immune response in patients with Guillain-Barré syndrome. J Neurol 1996;243:264-8.
14. Zhu J, Mix E, Olsson T, et al. Cellular mRNA expression of interferon-gamma, IL-4 and transforming growth factor-beta (TGF-beta) by rat mononuclear cells stimulated with peripheral nerve myelin antigens in experimental allergic neuritis. Clin Exp Immunol 1994;98:306-12.
15. Rieckmann P, Albrecht M, Kitze B, et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994;44:1523-6.
16. Gherardi RK, Bélec L, Soubrier M, et al. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood 1996;87:1458-65.
17. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992;359:693-9.
18. Christ M, McCartney-Francis NL, Kulkarni AB, et al. Immune dysregulation in TGF-β1 deficient mice. J Immunol 1994;153:1936-46.
19. Asbury AK, Arnasson BG, Karp HR, et al. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 1978;3:565-6.
20. The French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997; 41:298-306.
21. Hughes RAC, Newsom-Davis JM, Perkins JD. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978; ii:750-3.
22. Childs CB, Proper JA, Tucker RF, et al. Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci USA 1982;79:5312-6.
23. Dubinett SM, Huang M, Dhanani S, et al. Down-regulation of macrophage transformation growth factor-beta messenger RNA expression by IL-7. J Immunol 1993;151:6670-80.
24. Sharp BM, Matta SG, Peterson PK, et al. Tumor necrosis factor-alpha is a potent ACTH secretagogue: comparison to interleukin-1 beta. Endocrinology 1989;124:3131-3.
25. Ayanlar Batuman O, Ferrero AP, Diaz A, et al. Regulation of transforming growth factor-β1 gene expression by glucocorticoids in normal human T lymphocytes. J Clin Invest 1991;88:1574-80.
26. Shull S, Meisler N, Absher M, et al. Glucocorticoid-induced down regulation of transforming growth factor-beta 1 in adult rat lung fibroblasts. Lung 1995;173:71-8.
27. Keramidas M, Chambaz EM, Feige JJ. Inhibition of adrenocortical steroidogenesis by α2-macroglobulin is caused by associated transforming growth factor β. Mol Cell Endocrinol 1992;84:243-51.
28. Alderson MR, Tough TW, Ziegler SF, et al. Interleukin-7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med 1991;173: 923-30.
29. Kiefer R, Streit WJ, Toyka KV, et al. Transforming growth factor-β1: a lesion-associated cytokine of the nervous system. Int J Dev Neuroscience 1995;13:331-9.
30. Miller A, Lider O, Roberts AB, et al. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering. Proc Natl Acad Sci USA 1992; 89:421-5.
31. Chen Y, Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis Science 1994;265:1237-40.
32. Gamble JR, Vadas MA. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-β1. J Immunol 1991;146:1149-54.
33. Tsunawaki S, Sporn M, Ding A, et al. Deactivation of macrophages by transforming growth factor-β. Nature 1988; 334:260-2.
34. Vodovotz Y, Bogdan C, Paik J, et al. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor β. J Exp Med 1993;178:605-13.
35. Czarniecki CW, Chiu HH, Wong GHW, et al. Transforming growth factor-β1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol 1988; 140:4217-23.
36. Jung S, Schluesener HJ, Schmidt B, et al. Therapeutic effect of transforming growth factor-β2 on actively induced EAN but not adoptive transfer EAN. Immunology 1994;83:545-51.
37. Johns LD, Flanders KC, Ranges GE, et al. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-β1. J Immunol 1991;147:1792-6.
38. Harpel JG, Metz CN, Kojima S, et al. Control of transforming growth factor-β activity: latency v activation. Prog Growth Factor Res 1992;4:321-35.
39. Lefaucheur J-P, Gjata B, Lafont H, et al. Angiogenic and inflammatory responses in injured skeletal muscle are altered by immune neutralization of endogenous bFGF, IGF-I or TGF-β1. J Neuroimmunol 1996;70:37-44.
40. Kiefer R, Funa K, Schweitzer T, et al. Transforming growth factor-β1 in experimental autoimmune neuritis. Cellular localization and time course. Am J Pathol 1996;148:211-23.
41. Roberts AB, Joyce ME, Bolander ME, et al. Transforming growth factor beta (TGF-β): a multifunctional effector of both soft and hard tissue regeneration. In: Westermark B, Betsholtz C, Hökfelt B, eds. Growth factors in health and disease: basic and clinical aspects. Amsterdam: Excerpta Medica, 1990:89-101.
42. Einheber S, Hannocks MJ, Metz CN, et al. Transforming growth factor-β1 regulates axon/Schwann cell interactions. J Cell Biol 1995;129:443-58.
43. Guenard V, Gwynn LA, Wood PM. Transforming growth factor-β blocks myelination but not ensheathment of axons by Schwann cells in vitro. J Neurosci 1995;15:419-28.
44. Rogister B, Delree P, Leprince P, et al. Transforming growth factor β as a neuronoglial signal during peripheral nervous system response to injury. J Neurosci Res 1993;34:32-43.
45. Chalazonitis A, Kalberg J, Twardzick DR, et al. Transforming growth factor β has neurotrophic actions on sensory neurons in vitro and is synergistic with nerve growth factor. Dev Biol 1992;152:121-32.